MONISTAT 1 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 1 COMBINATION PACK (MONISTAT 1 COMBINATION PACK).
Miconazole inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death. Miconazole also has direct anti-inflammatory and antibacterial properties.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways, likely involving cytochrome P450 enzymes, with minor metabolism by reductases. The major metabolites are inactive and excreted in urine and feces. |
| Excretion | Fecal: Approximately 90% of absorbed dose; Renal: <2% as unchanged drug; Biliary: Minor, less than 10%. |
| Half-life | Terminal elimination half-life: 24-30 hours (range 20-50 hours). Clinical context: Once-daily dosing may be considered for some indications, but prolonged half-life supports weekly or twice-weekly regimens for systemic infections. |
| Protein binding | Approximately 90% bound to plasma proteins (mainly albumin); limited binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd: 0.12-0.15 L/kg (12-15 L in 70 kg adult). Clinical meaning: Low Vd indicates limited tissue distribution; primarily confined to plasma and interstitial fluid. |
| Bioavailability | Intravaginal: Systemic absorption <1% after single dose; Oral: 40-50% (females) and 30-40% (males); Rectal: Not established for systemic use. |
| Onset of Action | Intravaginal: Local antifungal effect within 24 hours; Systemic: Not applicable for local use; oral formulation (if taken) requires 2-4 hours for detectable plasma levels. |
| Duration of Action | Intravaginal: Single dose provides therapeutic concentrations for up to 72 hours; Clinical note: Complete eradication of Candida may require longer treatment, typically 1-7 days. |
Miconazole nitrate 1200 mg vaginal suppository inserted intravaginally once at bedtime; plus external miconazole nitrate 2% cream applied to affected area twice daily for up to 7 days.
| Dosage form | CREAM, INSERT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients less than 12 years of age. |
| Geriatric use | No specific dose adjustment required; use as directed for adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 1 COMBINATION PACK (MONISTAT 1 COMBINATION PACK).
| Breastfeeding | Miconazole is poorly absorbed systemically after vaginal application. It is not known if it is excreted in human breast milk. The manufacturer recommends caution, but the risk to the nursing infant is minimal due to low systemic absorption. M/P ratio is unknown. |
| Teratogenic Risk | Miconazole is a Pregnancy Category C drug. Limited human data; no teratogenic effects have been reported in animal studies at clinically relevant doses. Risk cannot be ruled out, and use is generally avoided in the first trimester unless clearly needed. |
■ FDA Black Box Warning
No FDA black box warnings.
| Serious Effects |
["Hypersensitivity to miconazole or any component of the product","Not for use in patients with known hypersensitivity to imidazole antifungals"]
| Precautions | ["For vaginal use only; do not use orally or ophthalmically.","If symptoms persist or recur within 2 months, seek medical evaluation.","May cause local irritation, burning, or allergic reactions.","Use during pregnancy only if clearly needed (Category C).","Avoid use with diaphragms or condoms as product may damage latex."] |
Loading safety data…
| Fetal Monitoring |
| No specific maternal or fetal monitoring is required with single-dose vaginal miconazole. Standard obstetric care should continue. |
| Fertility Effects | There are no known adverse effects on fertility from vaginal miconazole. Animal studies have not shown impairment of fertility. |